CLS

Stimufend® (pegfilgrastim-fpgk) Now Available in the United States

Retrieved on: 
Thursday, February 16, 2023

Stimufend is available in a single-dose, pre-filled syringe that delivers 6mg/0.6mL solution for subcutaneous injection.

Key Points: 
  • Stimufend is available in a single-dose, pre-filled syringe that delivers 6mg/0.6mL solution for subcutaneous injection.
  • Additionally, more than 220 chemotherapy regimens can be supported entirely by administering Fresenius Kabi products.
  • Limitations of Use: Stimufend® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
  • To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Lieff Cabraser and Corpus Law Patel File Federal Class Action in Georgia Against Mercedes-Benz Over Dangerous Subframe Rust and Corrosion in 2010-2022 Model Year Mercedes Vehicles

Retrieved on: 
Friday, February 10, 2023

Plaintiffs allege that the vehicle subframes prematurely rust and corrode, costing consumers thousands of dollars in repairs that Mercedes has refused to cover.

Key Points: 
  • Plaintiffs allege that the vehicle subframes prematurely rust and corrode, costing consumers thousands of dollars in repairs that Mercedes has refused to cover.
  • The rust and corrosion can adversely affect driveability, lead to corrosion of other components on the underside of the vehicles, or cause the rear subframes to fail while the vehicles are in motion.
  • Corpus Law Patel partner Ketan A. Patel, who represents the owners who are suing, emphasized: “This is a serious safety concern.
  • Corrosion on the rear subframe makes the component and its attached suspension parts structurally unstable and prone to failure.

Campus Life & Style Awarded the Management of Two San Diego Student Housing New Developments

Retrieved on: 
Friday, February 17, 2023

AUSTIN, Texas, Feb. 17, 2023 /PRNewswire-PRWeb/ -- Campus Life & Style (CLS), one of the nation's leading operators of student housing communities, today announced it has been awarded the management of two student housing communities totaling 315 beds that are being developed by Next Space Development based in San Diego. The purpose-built student housing developments, StateSide and Monte are located on Montezuma Rd which allows for its residents to be within a 2-min walking distance of campus and across the street from San Diego State University (SDSU) Residential Halls.

Key Points: 
  • CLS announces that it has expanded its management portfolio to California, as they been awarded the management of two student housing properties located in San Diego.
  • AUSTIN, Texas, Feb. 17, 2023 /PRNewswire-PRWeb/ -- Campus Life & Style (CLS), one of the nation's leading operators of student housing communities, today announced it has been awarded the management of two student housing communities totaling 315 beds that are being developed by Next Space Development based in San Diego.
  • The inevitable success of these deals will continue to inspire further deals in the market which are all steps from campus.
  • Both developments deliver high-quality student housing, and pedestrian to campus, which will benefit SDSU and fuel local economic growth for decades to come.

V.tal kicks off its second Edge Data Center in Fortaleza, Brazil

Retrieved on: 
Friday, February 3, 2023

The unit will start operation with a 4 MW capacity and will have four "data halls" with space to accommodate 400 racks.

Key Points: 
  • The unit will start operation with a 4 MW capacity and will have four "data halls" with space to accommodate 400 racks.
  • The new edge data center is fully integrated with its undersea cable landing station (CLS - Cable Landing Station).
  • It has connection redundancy, which ensures data transmission security.
  • The unit will also be integrated with the other company's edge data center in Fortaleza.

Hemcheck has received a follow up order from its UK distributor

Retrieved on: 
Wednesday, February 1, 2023

SOLNA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its UK distributor, CLS.

Key Points: 
  • SOLNA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its UK distributor, CLS.
  • The order concerns instruments for diagnostic use and bgs-Tests and is of smaller economic value.
  • - Orders continue to come in, which is very positive.
  • It is mainly products for diagnostic use that show good potential and as the British market is very large, we hope for more orders from there, says Joen Averstad, CEO of Hemcheck.

CLS Americas and HALO Precision Diagnostics Announce 25 Patient Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System

Retrieved on: 
Wednesday, February 8, 2023

HALO will conduct an initial post-market study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers.

Key Points: 
  • HALO will conduct an initial post-market study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers.
  • Upon completion of its evaluation, HALO and CLS will enter into discussions regarding HALO’s acquisition of the CLS TRANBERG Laser System for use in some of its nationwide system of approximately 16 clinics.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • The TRANBERG system can be deployed in either a transperineal or transrectal approach.

GST Awarded as a Prime Contractor on $900 Million Four-Year Base JE-CLaSS II Contract

Retrieved on: 
Friday, February 3, 2023

YARDLEY, Pa., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Global Systems Technologies, Inc. (GST) has been awarded a $900 million, four-year base and one four-year option period contract to support the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Key Points: 
  • YARDLEY, Pa., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Global Systems Technologies, Inc. (GST) has been awarded a $900 million, four-year base and one four-year option period contract to support the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
  • The IDIQ contract, Joint Enterprise Contracted Logistics and Services Support II (JE-CLaSS II) is designed as a streamlined, quick response vehicle to provide contractor logistics support (CLS) and related services for JPEO-CBRND developed and/or managed systems.
  • GST's contract spans both unrestricted and small business suites (Domains 1 and 2).
  • GST is headquartered in Yardley, PA, with offices in Galloway, NJ, and Crystal City, VA.

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Retrieved on: 
Thursday, February 2, 2023

ALPHARETTA, Ga., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.

Key Points: 
  • These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.
  • Thomas A. Ciulla, M.D., M.B.A., Chief Medical Officer and Chief Development Officer, said, “The positive data from our OASIS Extension Study reinforces our belief that CLS-AX has the potential to reduce treatment burden in patients with wet AMD while maintaining stable visual acuity.
  • In all participants in the trial, CLS-AX was well tolerated and demonstrated an excellent safety profile across all timepoints and doses.
  • The OASIS Phase 1/2a trial is complete for both the 3-month dose-escalation portion and the 3-month Extension Study.

CLS Americas and URN Announce Treatment of 20th & Final Patient in Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”

Retrieved on: 
Tuesday, January 31, 2023

The study is being conducted by Urological Research Network, LLC , a Florida-based, not-for-profit clinical research organization.

Key Points: 
  • The study is being conducted by Urological Research Network, LLC , a Florida-based, not-for-profit clinical research organization.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
  • “CLS Americas is very pleased with the preliminary results indicating patients experiencing little to minor quality of life side effects following the FLA procedure with the CLS TRANBERG laser system,” stated Michael Magnani, President of CLS Americas.

Celestica Announces 2023 Annual Meeting of Shareholders

Retrieved on: 
Thursday, January 26, 2023

TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today announced that the Annual Meeting of its Shareholders (the “Meeting”) will be held on Thursday, April 27, 2023 at 9:30 a.m. EDT in a virtual format.

Key Points: 
  • TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today announced that the Annual Meeting of its Shareholders (the “Meeting”) will be held on Thursday, April 27, 2023 at 9:30 a.m. EDT in a virtual format.
  • Celestica also announced that it has set Friday, March 10, 2023 as the record date for determining shareholders of the company who are entitled to receive notice of, and to vote at, the Meeting.
  • Celestica will be using the notice-and-access method for delivering the company’s proxy statement and related materials to shareholders eligible to participate at the Meeting.
  • The platform for the Meeting will provide shareholders the ability to listen to the Meeting live, submit questions and submit their vote during the Meeting.